[Flow cytometry for testing chemosensitivity of malignant bone tumors]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Malignant bone tumors exhibit variable responses to chemotherapy.
• Multidrug resistance (MDR) is a significant challenge in treating these cancers.
• Personalized chemotherapy protocols are needed to improve treatment efficacy.

Purpose of the Study:

• To assess the chemosensitivity and multidrug resistance of malignant bone tumors.
• To develop individualized chemotherapy protocols using sensitive antitumor agents.
• To investigate the role of P-glycoprotein (P170) in drug resistance.

Main Methods:

• Chemosensitivity and apoptosis were analyzed in 32 fresh malignant bone tumor specimens using flow cytometry (FCM) and quantitative immunofluorescence.
• The expression of P-glycoprotein (P170) was detected.
• Apoptosis was induced by Methotrexate (MTX), Adriamycin (ADM), Mitomycin C (MMC), Etoposide (VP-16), Vincristine (VCR), and Cyclophosphamide (CTX).

Main Results:

• Significant differences in apoptosis rates were observed across different chemotherapeutic agents.
• Methotrexate (MTX) induced the highest apoptosis rate (30.50 +/- 10.22%), while Cyclophosphamide (CTX) showed the lowest (1.22 +/- 0.59%).
• High expression of P-glycoprotein (P170) correlated with lower chemosensitivity in malignant bone tumors.

Conclusions:

• Flow cytometry is a simple, rapid, and sensitive method for chemosensitivity testing in malignant bone tumors.
• Quantitative analysis of P170 expression can predict multidrug resistance and guide chemotherapy selection.
• Individualized treatment strategies based on chemosensitivity testing can optimize chemotherapy for bone cancer patients.